NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares" src="https://www.abnewswire.com/upload/2026/07/1782921889.jpg" alt="IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares" width="225" height="225">IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company developing Alzheimer's disease therapeutics and AI-enabled healthcare technologies, disclosed in a Form 4 filing that two senior executives increased their ownership stakes through debt-for-equity transactions.
According to the filing dated July 1, 2026, Director and Principal Financial Officer Claudia Grimaldi acquired 2,048,378 shares of IGC Pharma common stock at $0.27 per share in exchange for the cancellation of approximately $553,062 of debt owed to her by the company. Following the transaction, Grimaldi directly owns 3,421,092 shares. Form 4 IGC Pharma Inc (NYSE: IGC): July 1, 2026
In a separate transaction, Chief Executive Officer Ram Mukunda acquired 2,226,475 shares at $0.27 per share by cancelling approximately $601,148 of indebtedness owed to him by the company. Following the acquisition, Mukunda directly owns 6,875,563 shares of IGC Pharma common stock. Form 4 IGC Pharma Inc (NYSE: IGC): July 1, 2026
The transactions were completed as private placements under the exemption provided by Section 4(a)(2) of the Securities Act of 1933. The shares were issued as restricted securities under Rule 144 and were approved in advance by disinterested members of the Board of Directors and the Audit Committee for Rule 16b-3 purposes.
The insider transactions come as IGC Pharma continues advancing its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's dementia, while also expanding its proprietary Artificial Intelligence (AI) platform designed to accelerate drug discovery and clinical research.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
